Delcath Systems announces publication on SIRT in Cancers journal

Delcath Systems announced the publication of an article entitled “Selective Internal Radiotherapy, or SIRT, and Chemosaturation Percutaneous Hepatic Perfusion, or CS-PHP, for Metastasized Uveal Melanoma: A Retrospective Comparative Study” in the peer reviewed oncology journal Cancers. CS-PHP utilizes CHEMOSAT, Delcath’s proprietary European CE Marked Hepatic Delivery System, or HDS, to administer high-dose chemotherapy, or melphalan, to the liver, while controlling systemic exposure and associated side effects during a PHP procedure. Initial findings were previously presented on September 9, 2023 at the Cardiovascular and Interventional Radiological Society of Europe, or CIRSE, Annual Meeting held in Copenhagen, Denmark. Uveal melanoma usually shows a liver-dominant metastasis spread and is often treated with liver directed therapies. This retrospective study compared two cohorts of patients with liver dominant uveal melanoma treated at the University Hospitals Tubingen, Germany with multiple cycles of either CS-PHP or SIRT. Patients included in the study were treated between December 2013 and February 2020. Allocation to treatment was determined by a multidisciplinary team. Presence of extrahepatic disease at baseline favored the SIRT group , as did the hepatic tumor load. Tumor responses were evaluated by consensus reading by two experienced radiologists.